Global patents in the field of CAR-T cell therapy show a changing landscape with fierce competition and intensive collaboration.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Tri©DB: an integrated platform of knowledgebase and reporting system for cancer precision medicine
Journal of Translational Medicine Open Access 06 December 2023
-
A new era of macrophage-based cell therapy
Experimental & Molecular Medicine Open Access 01 September 2023
-
Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing
Molecular Cancer Open Access 26 June 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hoos, A. Nat. Rev. Drug Discov. 15, 235–247 (2016).
Tang, J., Pearce, L., O’Donnell-Tormey, J. & Hubbard-Lucey, V. M. Nat. Rev. Drug Discov. 17, 783–784 (2018).
Tang, J., Hubbard-Lucey, V. M., Pearce, L., O’Donnell-Tormey, J. & Shalabi, A. Nat. Rev. Drug Discov. 17, 465–466 (2018).
Yip, A. & Webster, R. M. Nat. Rev. Drug Discov. 17, 161–162 (2018).
Centers for Medicare & Medicaid Services. Decision memo for chimeric antigen receptor (CAR) T-cell therapy for cancers (CAG-00451N) (2019); https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=291
National Health Service England. NHS England announces groundbreaking new personalised therapy for children with cancer (2018). https://www.england.nhs.uk/2018/09/nhs-england-announces-groundbreaking-new-personalised-therapy-for-children-with-cancer/
Ministry of Health, Labour and Welfare. Handling of regenerative medicine products on medical insurance (2019); https://www.mhlw.go.jp/stf/shingi2/0000212500_00025.html
US Patent and Trademark Office. Case IPR2015-01719, Patent 7,446,190B2 (2015); https://www.ptablitigationblog.com/wp-content/uploads/2017/01/604105.pdf
Jürgens, B. & Clarke, N. S. Nat. Biotechnol. 37, 370–375 (2019).
Smith, J. A., Arshad, Z., Thomas, H., Carr, A. J. & Brindley, D. A. Nat. Biotechnol. 35, 210–214 (2017).
Smith, J. A. et al. Nat. Biotechnol. 36, 1043–1047 (2018).
Moher, D., Liberati, A., Tetzlaff, J. & Altman, D. G. Ann. Intern. Med. 151, 264–269 (2009). W64.
European Patent Office: INPADOC extended patent family. https://www.epo.org/searching-for-patents/helpful-resources/first-time-here/patent-families/inpadoc.html (accessed 25 May 2020).
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. N. Engl. J. Med. 365, 725–733 (2011).
Kochenderfer, J. N. et al. Blood 116, 4099–4102 (2010).
Ruella, M. & June, C. H. Curr. Hematol. Malig. Rep. 11, 368–384 (2016).
Egelie, K. J., Graff, G. D., Strand, S. P. & Johansen, B. Nat. Biotechnol. 34, 1025–1031 (2016).
Tralau-Stewart, C. J., Wyatt, C. A., Kleyn, D. E. & Ayad, A. Drug Discov. Today 14, 95–101 (2009).
Feldmann, M. & Maini, R. N. Nat. Med. 9, 1245–1250 (2003).
Dolgin, E. Nat. Biotechnol. 35, 891–892 (2017).
Ahuja, G. & Katila, R. Strateg. Manage. J. 22, 197–220 (2001).
Rikap, C. Rev. Int. Polit. Econ. 26, 987–1021 (2019).
Martin-Laffon, J., Kuntz, M. & Ricroch, A. E. Nat. Biotechnol. 37, 613–620 (2019).
Raje, N. et al. N. Engl. J. Med. 380, 1726–1737 (2019).
Yan, Z. et al. Lancet Haematol. 6, 521–529 (2019).
Acknowledgements
The authors thank J. Smith from NDORMS, the University of Oxford, for insightful comments and G. Li from IQVIA for assisting with data processing. We are grateful to the University of Macau Library for providing effective data service and the University of Macau for financial support via the project MYRG2019-00011-ICMS.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Supplementary information
Supplementary Information
Supplementary Note, Figs. 1–5 and Tables 1–7
Supplementary Data
Spreadsheet of 12,431 patent documents included in study
Rights and permissions
About this article
Cite this article
Lyu, L., Feng, Y., Chen, X. et al. The global chimeric antigen receptor T (CAR-T) cell therapy patent landscape. Nat Biotechnol 38, 1387–1394 (2020). https://doi.org/10.1038/s41587-020-00749-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-020-00749-8
This article is cited by
-
Tri©DB: an integrated platform of knowledgebase and reporting system for cancer precision medicine
Journal of Translational Medicine (2023)
-
Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing
Molecular Cancer (2023)
-
A new era of macrophage-based cell therapy
Experimental & Molecular Medicine (2023)
-
The global patent landscape of mRNA for diagnosis and therapy
Nature Biotechnology (2023)
-
The global patent landscape of HER2-targeted biologics
Nature Biotechnology (2023)